Sinus DiseasepeppermintNCT07866937
Peppermint and Decongestant Technique on Chronic Sinusitis
A study testing Sinus self-massage and inhalation of steated boiled peppermint in people with Sinus Disease, run by Assiut University.
Trial summary
Chronic rhinosinusitis (CRS) is defined as persistent symptomatic inflammation of the nasal and sinus mucosa that lasts more than 3 months. Epidemiologic studies estimate that 10% to 15% of the US population has CRS with a prevalence of up to 12% in Western populations. Read more about this study
- Who is it for?
- Ages 65 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Sinus Disease
- What is being tested?
- Sinus self-massage and inhalation of steated boiled peppermint
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 108 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2026to 1 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 to 80 years
- All sexes
- Healthy volunteers accepted
- Older adult
Who may be able to join
- 1- Elderly patients able to communicate. 2- Elderly patients have chronic rhinosinusitis
Who cannot join
- Hypersensitivity 2-Bronchial asthma and spasmophilia 3- Gastroesophageal reflux disease (heartburn)
About this study
Official title: Clinical Effect of Peppermint and Decongestant Technique on Chronic Sinusitis Among the Elderly
Chronic rhinosinusitis (CRS) is defined as persistent symptomatic inflammation of the nasal and sinus mucosa that lasts more than 3 months. Epidemiologic studies estimate that 10% to 15% of the US population has CRS with a prevalence of up to 12% in Western populations. CRS is defined as the symptomatic inflammation of the nose and para nasals in uses with the distinction based on the duration of the complaints. CRS is typically described more broadly as an inflammatory disorder and the importance of specific microbial agents in driving the process remains controversial. It is not clear what medical therapy should be followed as the proper treatment for CRS. The most common treatment of CRS includes medical therapy and in cases resistant to medication, endoscopic sinus surgery might be an option. (Kamaneh et al., 2020).
Read the detailed description
CRS is mostly treated by antibiotics and intranasal steroids but due to limited evidence, results of treatment are unsatisfactory. Previous studies have not confirmed the efficiency of herbal medicine to treat rhinosinusitis, particularly in chronic cases. New investigations recommend that some herbal medicines, either alone or combined with other kinds of treatment might alleviate the symptoms of severe sinus infection (Pleis et al.,2010).
- Conditions
- Sinus Disease
- Being tested
- Sinus self-massage and inhalation of steated boiled peppermint
- Medical subject headings
- Paranasal Sinus Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sinus self-massage and inhalation of steated boiled peppermintBehavioural
The patient should inhale steam from boiled mint leaves twice daily and perform Sinus Self-Massage to relieve nasal and sinus congestion, in addition to taking the prescribed medications.
| Study group | Role | What they receive |
|---|---|---|
| study | Experimental | The patient should inhale steam from boiled mint leaves twice daily and perform Sinus Self-Massage to relieve nasal and sinus congestion, in addition to taking the prescribed medications. Receives: Behavioral: Sinus self-massage and inhalation of steated boiled peppermint |
| control | No intervention | routine hospital care |
What is being measured
The primary outcome is the main question the study is designed to answer.
rhinosinusitis-specific scale
the 22-item Sino Nasal Outcome Test (SNOT-22) will be used for measuring quality of life. Each item is categorized into 6 levels (0 for no problem to 5 for the problem is as bad as it can be). The total score is gained by adding the score of each item (range 0-110) with lower scores implying a better health-related quality of life. It covers a wide range of health-related quality of life that may affect patient outcomes. SNOT subscales include 5 questions on rhinological symptoms, 4 questions on ear/facial symptoms, 3 questions on sleep function and 6 questions on psychological function. As with the total SNOT scale, higher scores indicate worse symptoms and lower quality of life
Measured: 3 months
Visual Analog Pain Scale
It was adopted from Chiarotto et al. (2019) and used by the researcher to assess the severity of low back pain. Scoring system: The total scores of the visual analog pain scale ranged from (0-10);
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Oct 2026
- Study start1 Oct 2026 (estimated)
- Primary completion1 Dec 2027 (estimated)
- Study completion1 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sinus DiseaseStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 108 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Tasneem ahmed, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07866937
- Sponsor's protocol ID
- peppermint and decongestant
- Other IDs
- peppermint
- Acronym
- peppermint
- Status last verified
- Oct 2026
- First submitted
- 5 Oct 2026
- Last updated
- 8 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Effect of Peppermint and Decongestant Technique on Chronic Sinusitis Among the Elderly
- ClinicalTrials.gov ID
- NCT07866937
- Acronym / sponsor ID
- peppermint / peppermint and decongestant
- Conditions
- Sinus Disease
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 108 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Oct 2026 (estimated)
- Primary completion
- 1 Dec 2027 (estimated)
- Study completion
- 1 Dec 2027 (estimated)
- First posted
- 8 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic rhinosinusitis (CRS) is defined as persistent symptomatic inflammation of the nasal and sinus mucosa that lasts more than 3 months. Epidemiologic studies estimate that 10% to 15% of the US population has CRS with a prevalence of up to 12% in Western populations. CRS is defined as the symptomatic inflammation of the nose and para nasals in uses with the distinction based on the duration of the complaints. CRS is typically described more broadly as an inflammatory disorder and the importance of specific microbial agents in driving the process remains controversial. It is not clear what medical therapy should be followed as the proper treatment for CRS. The most common treatment of CRS includes medical therapy and in cases resistant to medication, endoscopic sinus surgery might be an option. (Kamaneh et al., 2020).
Detailed description
CRS is mostly treated by antibiotics and intranasal steroids but due to limited evidence, results of treatment are unsatisfactory. Previous studies have not confirmed the efficiency of herbal medicine to treat rhinosinusitis, particularly in chronic cases. New investigations recommend that some herbal medicines, either alone or combined with other kinds of treatment might alleviate the symptoms of severe sinus infection (Pleis et al.,2010).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| study | Experimental | Behavioral: Sinus self-massage and inhalation of steated boiled peppermintThe patient should inhale steam from boiled mint leaves twice daily and perform Sinus Self-Massage to relieve nasal and sinus congestion, in addition to taking the prescribed medications. |
| control | No intervention | –routine hospital care |
Who may qualify
- Ages
- 65 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Older adult
Key inclusion criteria (1 listed)
- 1- Elderly patients able to communicate. 2- Elderly patients have chronic rhinosinusitis
Key exclusion criteria (1 listed)
- Hypersensitivity 2-Bronchial asthma and spasmophilia 3- Gastroesophageal reflux disease (heartburn)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sinus self-massage and inhalation of steated boiled peppermintThe patient should inhale steam from boiled mint leaves twice daily and perform Sinus Self-Massage to relieve nasal and sinus congestion, in addition to taking the prescribed medications. | Behavioural | study |
Primary outcome
rhinosinusitis-specific scale
Time frame: 3 months
the 22-item Sino Nasal Outcome Test (SNOT-22) will be used for measuring quality of life. Each item is categorized into 6 levels (0 for no problem to 5 for the problem is as bad as it can be). The total score is gained by adding the score of each item (range 0-110) with lower scores implying a better health-related quality of life. It covers a wide range of health-related quality of life that may affect patient outcomes. SNOT subscales include 5 questions on rhinological symptoms, 4 questions on ear/facial symptoms, 3 questions on sleep function and 6 questions on psychological function. As with the total SNOT scale, higher scores indicate worse symptoms and lower quality of life
Visual Analog Pain Scale
Time frame: 3 months
It was adopted from Chiarotto et al. (2019) and used by the researcher to assess the severity of low back pain. Scoring system: The total scores of the visual analog pain scale ranged from (0-10);
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2026.
- Individual participant dataSharing planned: Yes
Related trials for Sinus Disease
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma
RecruitingObservational study
Danang Cerebral Venous Thrombosis Registry
Cerebral Venous Sinus Thrombosis, Stroke
RecruitingPhase 4
Risankizumab for Refractory Perianal Fistulizing Crohn's Disease
Crohn Disease, Perianal Fistula
Not yet recruiting
FESS With or Without Intranasal Desmopressin in Chronic Rhinosinusitis With Nasal Polyps
Chronic Sinusitis, Nasal Polyposis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Sinus self-massage and inhalation of steated boiled peppermint in people with Sinus Disease, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 8 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
rhinosinusitis-specific scale (time frame: 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2026.